Bio Path reported $-297K in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Baxter International USD 276M 210M Jun/2026
Bio Path USD -297K 191K Mar/2026
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026